Pharis Biotec GmbH
Records under this name other than the patents Pharis Biotec GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,045,563 | CXC Chemokine Receptor 4 (CXCR4) Antagonistic Polypeptide Formerly held In force · High confidence | In force | High confidence | |
| US 9,434,780 | Process for preparing human relaxin-2 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,294,272 | Peptides with antagonistic activities against natural CXCR4 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 6,831,064 | Use of urodilatin for treating chronic kidney failure with residual kidney functions Formerly held Term ended Term ended Aug 16, 2022 · From the USPTO record | Term ended | Term ended Aug 16, 2022 | From the USPTO record |
| US 8,293,711 | Use of natriuretic peptides for treating angioedema syndromes Formerly held Lapsed on the fee record Ended Oct 23, 2020 · From the USPTO record | Lapsed on the fee record | Ended Oct 23, 2020 | From the USPTO record |
| US 7,045,594 | Serine proteinase inhibitors Lapsed on the fee record Ended May 16, 2018 · From the USPTO record | Lapsed on the fee record | Ended May 16, 2018 | From the USPTO record |
| US 6,939,851 | Serine proteinase inhibitors Lapsed on the fee record Ended Sep 6, 2017 · From the USPTO record | Lapsed on the fee record | Ended Sep 6, 2017 | From the USPTO record |
| US 7,033,997 | Use of natriuretic peptides as antibiotically active substances for the treatment of bacterial infections Formerly held Lapsed on the fee record Ended Apr 25, 2014 · From the USPTO record | Lapsed on the fee record | Ended Apr 25, 2014 | From the USPTO record |
| US 6,849,593 | Bifidogenic peptides Lapsed on the fee record Ended Feb 1, 2013 · From the USPTO record | Lapsed on the fee record | Ended Feb 1, 2013 | From the USPTO record |
| US 6,809,175 | Cadherin derived growth factor and its use Lapsed on the fee record Ended Oct 26, 2012 · From the USPTO record | Lapsed on the fee record | Ended Oct 26, 2012 | From the USPTO record |